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The recent publication by Van Lunzen et al (HARNESS) evaluated the efficacy and safety of 
switching HIV infected adults from a stable regimen of 2 NRTIs with a third antiretroviral 
(ART) agent to either ritonavir boosted atazanavir (ATV/r) 300/100 mg plus tenofovir 
disoproxil fumarate and emtricitabine 300/200 mg once daily (ATV/r+TDF/FTC) or ATV/r 
plus raltegravir 400 mg twice daily (ATV/r+RAL)1. Interestingly a lower proportion of 
participants in the ATV/r+RAL arm maintained viral suppression at weeks 24 and 48. There 
was no immunologic benefit or reduction in adverse events with switching. In fact, 
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tolerability of the ATV/r+RAL arm was lower due to dyslipidemia and pill burden. We also 
performed a study evaluating an NRTI sparing regimen in treatment naïve HIV infected 
persons using a similar approach.
From October 2008 to November 2009, the California Collaborative Treatment Group 
(CCTG) performed a randomized, open-label 48 week, multicenter study comparing the 
efficacy, safety and tolerability of RAL + ritonavir boosted lopinavir (LPV/r) 400/100 mg 
twice daily to a fixed dose combination of efavirenz 600 mg (EFV)+ TDF/FTC daily 
(EFV/TDF/FTC) in HIV-infected, treatment naïve subjects (N=51). The study was approved 
by local institutional review boards and all participants underwent informed consent prior to 
enrollment. Fifty-one subjects were randomized (25 in EFV/TDF/FTC and 26 in RAL
+LPV/r) and included in the analyses with documentation of baseline characteristics, HIV-1 
RNA, CD4 cell counts and resistance testing. The primary efficacy analysis used a linear 
mixed effects model to assess the difference in the HIV RNA decay rates in the first 2 weeks 
between the treatment groups. Repeated HIV RNA Measured at baseline, day 2, 7, 10 and 
14 were treated as the outcome. The fixed effects included time, treatment group, and 
treatment group-by-time interaction. The random effects included both intercept and slope. 
Secondary analysis also compared the proportion of subjects with undetectable RNA (HIV 
viral load < 50 copies/mL) at weeks 4, 8, 12, 16, 24, 36 and 48 between the two groups 
using Fisher's exact test.
The majority (96%) of participants were men; with a median age of 43 years (IQR: 31, 48). 
Eighty-four percent were White and 9.8% Black with 51% Hispanic. The median baseline 
viral load was 4.7 log10 copies/mL (IQR: 4.1,4.9), the median CD4 count was 358 
cells/mm3 (IQR: 176, 459). There were no statistically significant differences in the baseline 
characteristics between treatment arms.
Compared with those in the EFV/TDF/FTC arm, participants in the RAL+LPV/r group 
demonstrated significantly more rapid viral decay in the first two weeks (-0.16 vs -0.13 
log10/day, p=0.0007) and a higher proportion demonstrated an undetectable HIV RNA at 
week 4 (54% vs 12% p = 0.003). However, no differences in viral suppression between the 
two groups were observed and at week 8 and week 48 (86% vs 87.5%, p>0.99, figure 1). No 
differences were observed in the CD4 T cell dynamics between the arms over the 48 weeks. 
Unlike HARNESS we did not observe the presence of integrase strand transfer inhibitor 
(INSTI) resistance in person failing RAL + LPV/r.
We also evaluated self-reported adherence (ACTG recall questionnaire) as the RAL+LPV/r 
arm necessitated a higher pill count and more frequent dosing than EFV/TDF/FTC. Overall 
assuming missing equals not adherent, the proportion of subjects with perfecta dherence was 
low (25%) in this study with the EFV/TDF/FTC arm demonstrating a slightly higher but not 
significantly different proportion with adherence than the RAL+LPV/r arm (36% vs 15%, 
respectively, p=0.12). Frequency of all reported adverse events also showed no significant 
difference between the two arms (60% in the EFV/TDF/FTC arm vs. 50% in the RAL
+LPV/r arm, p=0.58).
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In CCTG 589 initiation of RAL+LPV/r did result in a higher proportion of participants 
achieving an undetectable HIV VL at week 4, as would be expected with an INSTI based 
regimen. However the difference in virologic suppression between arms was not sustained 
over time and did not result in immunologic benefit. There were no differences noted in 
terms of side effects, but persons on RAL+LPV/r did report lower rates of adherence.
The use of an INSTI combined with a protease inhibitor (PI) offers possible therapeutic 
advantages over nucleoside reverse transcriptase inhibitors combined with non-nucleoside 
reverse transcriptase in relation to: (1) antiviral potency given the combination of both late 
(PI) and mid-cycle (INSTI) viral target inhibitors allowing for more efficient termination of 
viral replication from cellular reservoirs and more rapid early plasma viral decay2,3, and (2) 
immune recovery4-7. Studies of combination therapy with INSTI+PI in HIV infected persons 
who are naive to therapy have demonstrated rapid early plasma viral decay, which may be 
beneficial in that it minimizes onward HIV transmissions8. This may have benefit in select 
patients where the goal is rapid virologic suppression such as in pregnant women with a 
detectable HIV viral load. Additionally, studies evaluating INSTI + PI therapy do not 
document long term virologic or immunologic benefit8-10, but some studies (a switch study 
and an NRTI and ritonavir sparing study) did demonstrate a higher risk for development of 
INSTI resistance mutations1,9 and in at least one study in ART-naïve showed a higher failure 
rate in subjects with low CD4 and HIV viral loads > 100,000 copies/mL8. These 
observations have led to the recommendations from multiple guideline panels that inclusion 
of NRTIs in patients who are ART naïve or switching ART is the preferred treatment 
approach11. The interpretation of the results of CCTG 589 and HARNESS was limited by 
small sample sizes and adherence issues. Yet our experiences highlight that the use of a 
twice daily INSTI (RAL is the only INSTI evaluated in all the studies to date) combined 
with a PI is not an ideal regimen for routine care. It remains unknown if combinations of a 
PI with a daily INSTI confers additional virologic or immunologic benefits to people living 
with HIV and would benefit from further evaluation. However this question may be less 
relevant with the recent approval of the novel NRTI, tenofovir alafenamide which exhibits 
potent viral suppression and reduced toxicity.
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Figure 1. 
Proportion of study participants (A-dark gray EFV/FTC/TDF and B-light gray RAL+LPV/r) 
with an undetectable HIV viral load over time ignoring the missing RNA measurements due 
to early study discontinuation between week 4 and week 48. Significant difference are noted 
between arms at week 4 (with a higher proportion of persons in the RAL+LPV/r arm 
achieving an undetectable HIV viral load) but no difference is observed at week 48.
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